FOCAL OSTEOMALACIA DUE TO LOW-DOSE DIPHOSPHONATE THERAPY IN PAGET'S DISEASE

The Lancet

Volumn 323, Issue 8381, 1984, Pages 821-824

  Boyce, B F ^a   Fogelman, I ^a   Ralston, S ^a   Smith, Linda ^a   Johnston, Eve ^a   Boyle, I T ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; ETIDRONIC ACID;

ADVERSE DRUG REACTION; BONE; BONE BIOPSY; CLINICAL ARTICLE; DIAGNOSIS; DRUG DOSE; DRUG THERAPY; HUMAN; ORAL DRUG ADMINISTRATION; OSTEOLYSIS; OSTEOMALACIA; THERAPY;

AGED; BIOPSY; BONE AND BONES; BONE RESORPTION; ETIDRONIC ACID; FEMALE; HUMANS; MALE; MIDDLE AGED; MINERALS; OSTEITIS DEFORMANS; OSTEOGENESIS; OSTEOMALACIA;

EID: 0021328378     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(84)92272-4     Document Type: Article

References (24)

1. Paget's disease of bone: experience with a diphosphonate (disodium etidronate) in treatment
2. Diphosphonates in Paget's disease
3. Results of prolonged treatment of Paget's disease ofbone with disodium ethane-1-hydroxy-1, 1-diphosphonate (EHDP)
4. Diphosphonate treatment of Paget's disease of bone. A correlated metabolic, calcium kinetic and morphometric study
5. Effects of disodium dichloromethylene diphosphonate on Paget's disease of bone
6. Treatment of Paget's disease with (3-ammo-1-hydroxypropylidene)—1, 1-bisphosphonate (APD)
7. Hypercalcaemic osteomalacia due to aluminium toxicity
8. Tetracycline-based histological analysis of bone remodelling
9. Frequency distribution and "reference values" of plasma alkaline phosphatase (EC 3.1.3.1.) activity in the adult population of a Scottish new town
10. Age- and sex-related reference ranges of 8 plasma consituents derived from randomly selected adults in a Scottish new town
11. 3 in the management of senile osteoporosis: a pilot study
12. Osteomalacia. Current concepts
13. Experimental basis for the clinical use of diphosphonates in Paget's disease of bone
14. Sodium etidronate in the treatment of Paget's disease ofbone A study of long-term results
15. Effects of ethane—1- hydroxy-1 1-diphosphonate (5 mg/kg/day dose) on quantative bone histology in Paget's disease of bone
16. Diphosphonates and inhibition of bone mineralisation
17. Diphosphonates and inhibition of bone mineralisation
18. Clinical and biochemical effects of diphosphonates in Paget's disease of bone
19. Diphosphonate treatment of Paget's disease
20. Etidronate disodium in the treatment of Paget's disease of bone
21. Review of fracture experience during treatment of Paget's disease of bone with etidronate disodium (EHDP
22. Roentgenologic evaluation of the action of the diphosphonate EHDP and of combined therapy (EHDP and calcitonin) in Paget's disease of bone
23. Fracturing dialysis osteodystrophy and dialysis encephalopathy
24. Histologic changes in Paget's disease treated with calcitonin